Patients ( N = @ ) with stage II to III TNBC received paclitaxel @ mg/m ( @ ) once per week ( wP ) for @ weeks , followed by doxorubicin plus cyclophosphamide once every @ weeks ( ddAC ) for four cycles , and were randomly assigned to concurrent carboplatin ( area under curve @ ) once every @ weeks for four cycles and/or bevacizumab @ mg/kg once every @ weeks for nine cycles .